| Basics |
Axsome Therapeutics, Inc.
Axsome Therapeutics Inc is a pharmaceutical company in the United States. It focuses on developing novel therapeutics for the redressal of diseases related to the central nervous system.
|
| IPO Date: |
November 19, 2015 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$6.25B |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$1.15 | 2.96%
|
| Avg Daily Range (30 D): |
$1.48 | 1.34%
|
| Avg Daily Range (90 D): |
$1.61 | 1.48%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.61M |
| Avg Daily Volume (30 D): |
.5M |
| Avg Daily Volume (90 D): |
.51M |
| Trade Size |
| Avg Trade Size (Sh.): |
76 |
| Avg Trade Size (Sh.) (30 D): |
39 |
| Avg Trade Size (Sh.) (90 D): |
39 |
| Institutional Trades |
| Total Inst.Trades: |
3,349 |
| Avg Inst. Trade: |
$2.98M |
| Avg Inst. Trade (30 D): |
$5.71M |
| Avg Inst. Trade (90 D): |
$5.99M |
| Avg Inst. Trade Volume: |
.04M |
| Avg Inst. Trades (Per Day): |
2 |
| Market Closing Trades |
| Avg Closing Trade: |
$3.67M |
| Avg Closing Trade (30 D): |
$5.96M |
| Avg Closing Trade (90 D): |
$7.24M |
| Avg Closing Volume: |
53.38K |
|
|
| Financials |
| |
TTM |
Q2 2025 |
Q1 2025 |
|
Basic EPS
|
$-5.07
|
$-.97
|
$-1.22
|
|
Diluted EPS
|
$-5.07
|
$-.97
|
$-1.22
|
|
Revenue
|
$ 495.03M
|
$ 150.04M
|
$ 121.46M
|
|
Gross Profit
|
$
|
$
|
$
|
|
Net Income / Loss
|
$ -246.9M
|
$ -47.97M
|
$ -59.41M
|
|
Operating Income / Loss
|
$ -228.94M
|
$ -36.71M
|
$ -56.98M
|
|
Cost of Revenue
|
$
|
$
|
$
|
|
Net Cash Flow
|
$ -12.64M
|
$ 2.11M
|
$ -14.44M
|
|
PE Ratio
|
|
|
|
|
|
|
